Related Experiment Videos
Benzodiazepine dependence: detoxification under standardized conditions
P M Brenner1, B Wolf, T Rechlin
1Department of Psychiatry, University of Munich, Germany.
Drug and Alcohol Dependence
|December 31, 1991
Summary
This study found a safe and effective inpatient benzodiazepine (BZD) dose reduction schedule for dependent patients. Most withdrawal symptoms resolved within 10 days of stopping BZD use.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Medicine
Background:
- Benzodiazepine (BZD) dependence is a significant clinical concern.
- Understanding withdrawal syndromes is crucial for patient management.
- Factors influencing BZD withdrawal require detailed investigation.
Purpose of the Study:
- To analyze the benzodiazepine (BZD) withdrawal syndrome in dependent patients.
- To identify factors influencing the withdrawal process.
- To evaluate a standardized inpatient dose reduction protocol.
Main Methods:
- Analysis of 12 patients undergoing BZD withdrawal under inpatient conditions.
- Gradual BZD dose reduction by 50% every 5 days.
- Monitoring withdrawal symptoms using Lader's BZD withdrawal symptom checklist and urine BZD concentrations.
Main Results:
- The dose reduction scheme was safe and efficient, with no major withdrawal syndromes observed.
- Somatic, psychological, and perceptual withdrawal phenomena were documented.
- Abstinence symptoms largely resolved within 10 days of BZD discontinuation.
Conclusions:
- A standardized inpatient BZD dose reduction protocol is effective and safe.
- Early resolution of withdrawal symptoms is achievable with this method.
- Further research into influencing factors can optimize BZD withdrawal management.